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0. Abstract 
 
Major depressive disorder (MDD) is a prevalent disorder with moderate heritability. 
Both MDD and interpersonal adversity, including childhood maltreatment, have been 
consistently associated with elevated inflammatory markers. We investigated 
interaction between exposure to childhood maltreatment and extensive genetic 
variation within the inflammation pathway (CRP, IL1b, IL-6, IL11, TNF, TNFR1, and 
TNFR2) in relation to depression diagnosis. The discovery RADIANT sample 
included 262 cases with recurrent DSM-IV/ICD-10 MDD, and 288 unaffected 
controls. The replication Münster cohort included 277 cases with DSM-IV MDD, and 
316 unaffected controls. We identified twenty-five single nucleotide polymorphisms 
(SNPs) following multiple testing correction that interacted with childhood 
maltreatment to predict depression in the discovery cohort. Seven SNPs 
representing independent signals (rs1818879, rs1041981, rs4149576, rs616645, 
rs17882988, rs1061622, and rs3093077) were taken forward for replication. Meta-
analyses of the two samples presented evidence for interaction with rs1818879 (IL6) 
(RD=0.059, SE=0.016, p < 0.001), with the replication Münster sample approaching 
statistical significance in analyses restricted to recurrent MDD and controls following 
correction for multiple testing (q=0.066). The CRP locus (rs3093077) showed a 
similar level of evidence for interaction in the meta-analysis (RD=0.092, SE=0.029, 
p=0.002), but less compelling evidence in the replication sample alone (recurrent 
MDD q=0.198; all MDD q=0.126). Here we present evidence suggestive of 
interaction with childhood maltreatment for novel loci in IL-6 (rs1818879) and CRP 
(rs3093077), increasing risk of depression. Replication is needed by independent 
groups, targeting these specific variants and interaction with childhood maltreatment 
on depression risk. 
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1. Introduction 
 
Major depressive disorder (MDD) is a highly prevalent disorder that represents a 
substantial economic as well as clinical burden (Mortality and Causes of Death, 
2016). Heritability has been well-established and estimates from population-based 
studies range between 31-42% (Sullivan et al., 2000), with higher estimates of 
around 70% based on clinical or more severe cases (McGuffin et al., 2007). Many 
studies have attempted to identify genes associated with the disorder, however 
despite significant improvements in genotyping platforms, and large-scale increases 
in sample sizes, consistently replicated genetic variants remain elusive (Major 
Depressive Disorder Working Group of the Psychiatric Consortium et al., 2013). This 
may be for multiple reasons, including failure of most association studies to take into 
account the role of stress in the development of MDD (Cohen-Woods et al., 2013; 
Hosang et al., 2012; Thapar et al., 2012).  
 
The first reported specific gene–environment (GE) interaction in MDD was with the 
serotonin transporter polymorphism, 5HTTLPR and this has proven controversial 
(Uher and McGuffin, 2010). Recent meta-analyses indicate that the variable being 
measured (i.e. childhood stress vs. adult recent stress vs. medical illness) can 
impact findings, and highlight the need for replication (Karg et al., 2011), with the 
most recent failing to confirm a robust GE interaction with the 5HTTLPR and life 
events (Culverhouse et al., 2017). GE studies face significant methodological 
challenges with recommendations for future candidate gene-environment studies 
including: reporting all statistical tests conducted for a novel candidate GE study, 
applying appropriate corrections for statistical testing, and replication (Duncan et al., 
2014).  
 
Elevated inflammation has been associated with both MDD and exposure to 
childhood traumatic events. Our study focuses on genes where proteins in the 
periphery have been associated with both MDD and childhood maltreatment (CRP, 
IL-6, TNF), genes where GE interactions have previously been reported that include 
childhood or adolescent stressors (IL-1b, IL6), or genes associated with anti-
depressant response in caucasian MDD patients (IL-11); poor anti-depressant 
response has been reported in individuals with a history of childhood maltreatment 
(Williams et al., 2016). Elevations of many inflammatory proteins have been reported 
in patients with MDD including C-reactive protein (CRP), tumour necrosis factor 
(TNF), and interleukin-6 (IL-6) (Dowlati et al., 2010; Howren et al., 2009). Further, 
psychological stressors, including early-life maltreatment, have been consistently 
associated with elevated inflammatory markers (Baumeister et al., 2016; Danese et 
al., 2008; Fagundes et al., 2013; Kiecolt-Glaser et al., 2011), supported by animal 
models (Ganguly and Brenhouse, 2015).  
 
Most studies to date have focused on protein analyses, and are limited in number; 
many more studies have genetic data available rather than serum or plasma, which 
is necessary for peripheral protein analyses. For this reason investigating genetic 
variants that have potential to impact gene- and protein- expression in the context of 
stressful life events is of value. There is also some evidence for interaction with 
genetic variants in IL-1b and IL-6 and chronic recent stress exposure predicting 
depressive scores in Australian youth (Tartter et al., 2015), and IL-1b predicting 
depressive symptoms in preschoolers exposed to childhood maltreatment (Ridout et 
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al., 2014), and IL-11 with anti-depressant response (Uher et al., 2010). Other genes 
in the inflammation pathway have been associated with anti-depressant response 
(e.g. (Barnes et al., 2017; Wong et al., 2008), however as our populations are 
caucasian, for this study we restricted to genes identified in Caucasian populations. 
Thus overall there are sound reasons for exploring genes involved in inflammation in 
GE research, looking at depressive disorder onset, course and exposure to stressors 
including childhood maltreatment (Baumeister et al., 2016; Grosse et al., 2016; 
Kiecolt-Glaser et al., 2015; Miller and Raison, 2016). 
 
In this paper we present the first investigation of the interaction between exposure to 
childhood stress and genetic variation, as captured by array, within the inflammation 
pathway. We focus on genes based on proteins and/or genes previously implicated 
in depression and with childhood maltreatment directly (CRP, IL1b, IL-6, IL11, and 
TNF), and indirectly (TNFR1, and TNFR2) (Camara et al., 2015; Danese et al., 2008; 
Goldsmith et al., 2016; Kiecolt-Glaser et al., 2015). This study aimed to address the 
recommendations by Duncan et al. (Duncan et al., 2014): including previously 
implicated GE loci (IL-6 (rs1800795) and IL-1b (rs16944)) (Tartter et al., 2015), by 
clearly reporting all statistical tests run, robust multiple testing correction and 
reporting, and independent replication, extended to a meta-analysis.  
 
2. Material and methods 
 
2.1 Participants 
 
2.1.1 Discovery sample  
Individuals were drawn from the Radiant MDD cohort recruited in the United 
Kingdom from three sites (Birmingham, Cardiff, and London), described in detail 
previously (Fisher et al., 2013; Lewis et al., 2010). In brief, MDD cases experienced 
a minimum of two DSM-IV/ICD-10 depressive episodes of moderate to severe 
severity (First, 1994), ascertained by interview in person with the Schedules Clinical 
Assessments Neuropsychiatry (SCAN) (Wing et al., 1990); DNA was extracted from 
whole blood. Exclusion criteria were history of substance-related disorders, mania or 
hypomania, mood-incongruent psychosis, and a first or second-degree relative with 
bipolar or psychotic disorder. Control individuals were screened to ensure they had 
no psychiatric history themselves, or in their first-degree relatives. The Radiant 
sample assessed for childhood trauma consisted of 262 cases (190 females, and 72 
males; mean age = 44.79 (±12.38)) and 288 controls (119 females, and 169 males; 
mean age = 47.49 (± 9.24)); DNA was extracted from saliva. Controls were excluded 
if they had a personal or first-degree relative with a history of any psychiatric 
disorder. All participants were white European, with parents and grandparents of 
white European origin, and aged 18 years or over. This study was approved by the 
local University and NHS Ethics Committees at each site and conformed to the 
Declaration of Helsinki (1975). All participants provided written informed consent. 
 
2.1.2 Replication sample 
To replicate findings, we used an independent cohort, the Münster Depression 
cohort described in detail elsewhere (Power et al., 2016). In brief, MDD cases were 
identified to have experienced a minimum of one DSM-IV/ICD-10 depressive 
episode, ascertained using the Structured Clinical Interview for DSM Disorders 
(SCID) (Wing et al., 1990). Exclusion criteria were any neurologic abnormalities, 
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substance-related disorders, psychotic symptoms, and/or a history of mania or 
hypomania. Control individuals were screened to have no psychiatric history 
themselves, also using the SCID. Exclusion criteria were scores ≥ 10 on the Beck 
Depression Inventory (BDI), any neurological abnormalities, history of seizures, head 
trauma or unconsciousness, intake of any psychotropic medication. The replication 
cohort included 277 adult cases (159 females, and 118 males; mean age = 40.27 (± 
11.89)) and 316 adult controls (177 females, and 139 males; mean age = 34.30 (± 
11.21)). Of the cases, 78% (n = 215) had experienced recurrent episodes of 
depression (125 females, and 90 males; mean age = 40.62 (± 11.74)) which 
represented our primary replication sample as this most closely reflected our 
discovery sample. All participants were white European, with parents and 
grandparents of white European origin, and aged 18 years or over. DNA was 
extracted from whole blood for all participants. This study was approved by the local 
University Ethics Committees and conformed to the Declaration of Helsinki (1975). 
All participants provided written informed consent. 
 
2.2 Measures 
 
2.2.1 Childhood maltreatment 
 
Self-reported emotional (EA), physical (PA), and sexual (SA) abuse, emotional (EN) 
and physical (PN) neglect during childhood were recorded using the Childhood 
Trauma Questionnaire (CTQ) (Bernstein et al., 2003) in both samples. We used 
standard coding methods detailed previously (Fisher et al., 2013) to classify each 
type of maltreatment and the overall maltreatment score into: 0 = None, 1 = Mild, 2 = 
Moderate or Severe. 
 
2.2.2 Genotyping of RADIANT discovery sample 
 
Sample collection  and DNA extraction methods have been described previously 
(Lewis et al., 2010). Genotyping was completed on the Illumina HumanHap610-
Quad BeadChips (Illumina Inc., San Diego, CA, USA) by the Centre National de 
Génotypage, and underwent stringent quality control as previously described. Quality 
control has been described in detail elsewhere (Lewis et al., 2010). Single nucleotide 
polymorphisms (SNPs) were imputed based on genotyping data collected using the 
HumanOmniQuad Array with 1000 Genome data as the reference panel with the 
IMPUTE.v2 program (Howie et al., 2009; Marchini and Howie, 2010). This employs 
combined reference panels of known phased haplotypes provided by HapMap 3 
(Feb 2009), 1000 Genomes Project (Mar 2010) (National Centre for Biotechnology 
Information build 36 coordinates) and the study's sample genotypes. Data were 
extracted for the inflammation genes and +/-5Kbs, and then converted to genotypes. 
SNPs with missing rates over 10%, info scores below 0.5, were monomorphic, with 
minor allele frequency below 5% and/or failed Hardy-Weinberg equilibrium (p < 
0.009) were excluded from analyses.  
 
2.2.2 Genotyping of Münster replication sample 
 
Genotyping of six of the replication SNPs in the Münster cohort was completed by 
the Australian Genome Research Facility (AGRF) using the Sequenom 
MassARRAY® iPLEX Gold assay (rs1041981, rs4149576, rs616645, rs17882988, 
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rs1061622, and rs3093077). We genotyped in-house one SNP using the TaqMan® 
SNP genotyping platform (rs1818879) due to incompatibility within the Sequenom 
multiplex. 99% of samples genotyped for SNPs rs4149576, rs17882988, rs1061622, 
and rs3093077, 98% for SNP rs1041981, and 97% for SNP rs1818879. One SNP 
failed to cluster (rs616645). 
 
2.3 Analysis 
 
Analyses were primarily conducted using Stata version 11.0. The main effects and 
interaction between childhood maltreatment and genotype on the presence/absence 
of recurrent unipolar depression were examined using a generalized linear 
model with the binomial distribution and identity link function specified 
(WACHOLDER, 1986) to estimate risk differences (RD) and 95% confidence 
intervals (CI); analyses were adjusted for gender. Tests that failed to converge in 
Stata were run in R Studio Version 0.99.491 using the blm function (Kovalchik et al., 
2013), a constrained maximum likelihood procedure that is operationally comparable 
to the iterative reweighted least squares (IRLS) algorithm of generalized linear 
models. We restricted analyses to additive interactions in additive genetic models in 
inflammation candidate genes. Additive models have been argued to provide the 
best representation of a biologically plausible interaction (Schwartz & Susser, 2006; 
Rothman et al., 1980) and are likely to be the most useful from a public health 
perspective (Kendler & Gardner, 2010). Meta-analyses were run using the metafor 
package in R. As no significant heterogeneity between studies was observed (p > 
0.05) we used a random effects model. 
 
In the discovery samples we applied multiple testing correction using SNPSpD 
(http://gump.qimr.edu.au/general/daleN/SNPSpD/) (Nyholt, 2004) to evaluate the 
number of independent markers within each gene. SNPSpD applies Nyholt’s method 
to estimate the Meff-Li p-value, accounting for non-independence between markers 
and avoiding overly conservative correction in the discovery sample (Nyholt, 2004). 
In total we analysed 120 SNPs across 7 genes (see Supplementary Table 4 for 
details including Meff-Li p-value thresholds) for interaction with childhood 
maltreatment in our discovery RADIANT sample. All SNPs targeted for replication 
were independent, thus the false discovery rate (Benjamini and Hochberg, 1995) 
was applied across SNPs analysed in the replication study.  
 
We tested for gene-environment correlation by testing association between genotype 
and childhood maltreatment category, in the discovery and replication samples, as 
replicated G-E correlations with SNPs also identified to be interacting SNPs 
significantly impacts conclusions we can draw (Dick, 2011). 
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3. Results 
 
3.1 RADIANT Discovery sample 
 
All forms of childhood maltreatment were significantly associated with greater risk of 
recurrent depression (Supplementary Table 1 for association, and Supplementary 
Table 10 for frequencies). All genotypes were in Hardy Weinberg Equilibrium, and 
there were no significant main effects of genotype on recurrent depression in the 
discovery Radiant sample, including adjustment for gender (Supplementary Table 2). 
No significant differences in overall severity of maltreatment was found by genotype 
amongst cases or controls following adjustment for gender and correction for 
multiple testing in IL-1b, IL-6, TNF, and CRP.  
 
In total 120 SNPs were analysed across the 7 genes; Supplementary Table 4 
presents interactions between all genotypes tested and over-all childhood 
maltreatment on the presence of recurrent depression. We report significant 
interactions with overall childhood maltreatment severity with 25 SNPs in 5 genes 
predicting risk of depression following multiple-testing correction (Table 1). The 
interactions observed represented two groups: those where the minor allele 
increased risk in those exposed to maltreatment (SNPs in IL-6 and CRP), and those 
where the major allele increased risk in the exposed group (SNPs in TNF, TNFR1, 
and TNFR2).  Seven of the 25 SNPs represented independent signals (LD < 0.80; 
see Supplementary Table 5): rs1818879 (IL-6), rs1041981 (TNF); rs4149576 
(TNFR1); rs616645 (TNFR2); rs17882988 (TNFR2); rs1061622 (TNFR2); and 
rs3093077 (CRP). No evidence for G-E correlation with childhood maltreatment and 
these SNPs is reported (Supplementary Table 3). 
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Gene  
Meff-Li p-value 
rsID Ref Alt 
Ref 
Freq 
Risk Difference (95% 
CI) p-value 
CRP  ≦0.009 rs3093077 T G 0.94 0.098 (0.024 - 0.172) 0.009 
IL-6  ≦0.006 rs1818879* G A 0.68 0.060 (0.017 - 0.103) 0.006 
TNF  ≦0.006 rs1041981 C A 0.64 0.070 (-0.119 - -0.021) 0.005 
TNFR1  ≦0.015 rs4149576 G A 0.6 -0.064 (-0.106 - -0.021) 0.004 
TNFR2  ≦0.005 rs616645* A C 0.81 0.083 (0.033 - 0.134) 0.001 
TNFR2  ≦0.005 rs17882988 G A 0.86 0.086 (0.034 - 0.137) 0.001 
TNFR2  ≦0.005 rs1061622* T G 0.77 0.053 (0.015 - 0.090) 0.006 
Table 1. SNPs presenting evidence for significant interaction with childhood maltreatment in prediction of risk of 
reporting recurrent depressive episodes in our discovery Radiant cohort. Analyses were adjusted for gender. rsID = rs 
number; Ref = reference allele; Alt = alternative allele; Ref Freq = frequency of reference allele; CI = confidence intervals. Meff-Li 
p-value represents SNPSpD identified p-value threshold for each gene. Only SNPs representing independent signals (R2 ≦ 0.80) 
included, for full data please see Supplementary Table 4. * = a constrained maximum likelihood procedure was applied, 
operationally comparable to the iterative reweighted least squares algorithm of generalized linear models; only if unconstrained 
analyses failed to converge
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3.2 Münster replication sample 
 
The 7 SNPs identified in the discovery sample passed quality control in our 
replication sample, except rs616645 (TNFR2) which was then excluded. Our 
primary replication analyses restricted the Münster replication sample to case 
individuals that had suffered multiple depressive episodes at recruitment (i.e. 
recurrent depression), more closely representing the discovery sample. 
Secondary analyses included the entire replication sample, allowing us to 
investigate if findings extended to individuals that had only experienced a 
single episode of depression. The replication sample confirmed all forms of 
childhood maltreatment were highly associated with greater risk of depression 
(Supplementary table 6 for association, and Supplementary Table 10 for 
frequencies). All genotypes were in Hardy Weinberg Equilibrium, and there 
were no differences in the distribution of genotypes between depressed cases 
and controls, with no main effects of genotype on recurrent depression 
(Supplementary Table 7). No significant differences in overall severity of 
maltreatment was found by genotype amongst cases or controls following 
adjustment for gender (Supplementary Table 8). Data presented in 
supplementary tables 6 - 8 demonstrate these effects are seen in both the 
primary recurrent depression replication Münster cohort, and the broader 
cohort that included individuals that had only experienced a single episode of 
depression. A SNP in IL-6 (rs1818879) presented evidence for interaction with 
overall childhood maltreatment severity to predict recurrent depression in the 
replication cohort, although this fell just short of significance following FDR 
correction (see Table 2). Nonetheless, the effect was in the same direction as 
in the discovery sample (see Figure 1). Meta-analysis of this locus with the 
two samples corroborated initial findings, indicating interaction with rs1817889 
(IL-6) and childhood maltreatment (see Figure 1(C): RD = 0.059, SE = 0.016, 
p < 0.001). 
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Recurrent Depression Depression (Recurrent and Single Episode) 
Gene rsID Risk Difference (95% CI) p-value q-value 
Risk Difference (95% 
CI) p-value q-value 
CRP rs3093077 0.083 (-0.006 - 0.172) 0.066 0.198 0.102 ( 0.015 - 0.189) 0.021 0.126 
IL-6 rs1818879 0.058 ( 0.013 - 0.102) 0.011 0.066 0.044 ( 0.001 - 0.087) 0.043 0.129 
TNF rs1041981 -0.002 (-0.079 - 0.074) 0.952 0.952 0.011 (-0.059 - 0.081) 0.762 0.762 
TNFR1 rs4149576 -0.007 (-0.077 - 0.064) 0.854 0.952 -0.015 (-0.082 - 0.052) 0.668 0.762 
TNFR2 rs1061622 0.010 (-0.064 - 0.084) 0.793 0.952 0.014 (-0.058 - 0.085) 0.705 0.762 
TNFR2 rs17882988 -0.015 (-0.107 - 0.077) 0.747 0.952 -0.021 (-0.110 - 0.068) 0.639 0.762 
Table 2. Interaction of discovery SNPs with childhood maltreatment in prediction of risk of reporting recurrent depressive 
episodes in our replication Münster cohort. Analyses were adjusted for gender. rsID = rs number; CI = confidence intervals; q-
value represents false discovery rate corrected p-value. Bold value: p-/q-value < 0.05. 
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Figure 1. Proportion of individuals with recurrent depression in (A) the discovery sample and (B) replication sample, by 
severity of different types of childhood maltreatment and IL-6 rs1818879 (A/G) genotype, and (C) forest plot and meta-
analysis of both samples. (A) and (B): y-axis shows probability of reporting recurrent depressive episodes; maltreatment severity 
is based on the Childhood Trauma Questionnaire (None, Mild, Moderate or Severe), with a rounded average score of all domains 
for overall maltreatment; the number of individuals included in each subgroup is given above each bar; underlined allele is the 
minor allele.  
A) Discovery Radiant Sample B) Replication Münster Cohort C) Meta-analysis of both cohorts 
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When the replication analysis was expanded to include the entire Münster 
replication sample, including those without a history of recurrent episodes, 
significance dropped drastically (Table 2).  
 
CRP (rs3093077) was close to significance, which reached non-corrected 
significance when analyses were expanded to include the whole replication 
sample and not just recurrent MDD individuals; however this was not 
significant with multiple testing correction (q>0.10; see Table 2). Figure 2 
presents visually the proportion of participants with recurrent depression, and 
any depression, for each level of childhood maltreatment severity by genotype 
analysed for CRP (rs3093077) in both the discovery and replication samples, 
showing that the effect was in the same direction. Meta-analysis of this locus 
with the two samples corroborated initial findings, indicating interaction with 
rs3093077 (CRP) and childhood maltreatment (see Figure 2(C): RD = 0.092, 
SE = 0.029, p = 0.002). 
 
No other SNPs presented evidence in the replication sample for the originally 
observed GE interactions in the discovery sample.  
 
  
Cohen-Woods Immunogenetics and depression 
 13
 
 
Figure 2. Proportion of individuals with recurrent depression in the (A) discovery sample and (B) replication sample, by 
severity of different types of childhood maltreatment and CRP rs3093077 (G/T) genotype, and (C) forest plot and meta-
analysis of both samples. (A) and (B): y-axis shows probability of reporting recurrent depressive episodes; maltreatment severity 
is based on the Childhood Trauma Questionnaire (None, Mild, Moderate or Severe), with a rounded average score of all domains 
for overall maltreatment; the number of individuals included in each subgroup is given above each bar; underlined allele is the 
minor allele.
A) Discovery Radiant Sample B) Replication Münster Sample 
1 
C) Meta-analysis of both cohorts 
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Stratified analyses on the basis of overall childhood maltreatment exposure 
(none, mild, and moderate to severe groups), support an effect of rs1818879 
and rs3093077 only in individuals with exposure to moderate to severe 
childhood maltreatment, with minor alleles increasing risk (Table 3). In the 
Radiant discovery sample there was suggestive evidence for a protective 
effect of rs1818879 in individuals who experienced no significant 
maltreatment in childhood, however this was not seen in the replication.  
 
Discovery RADIANT Sample Replication Münster Sample 
CM category Risk Difference (95% CI) p-value Risk Difference (95% CI) p-value 
rs1818879 
 
 
  
None -0.093 (-0.164 - -0.021) 0.011 -0.011 (-0.081 - 0.058) 0.747 
Mild 0.088 (-0.022 - 0.197) 0.115 -0.003 (-0.129 - 0.124) 0.967 
Moderate to 
Severe 0.052 ( 0.012 - 0.092) 0.013 0.103 ( 0.03 - 0.175) 0.006 
rs3093077 
      
None 0.009 (-0.131 - 0.150) 0.899 0.055 (-0.095 - 0.204) 0.475 
Mild 0.108 (-0.064 - 0.280) 0.218 0.021 (-0.258 - 0.300) 0.882 
Moderate to 
Severe 0.104 ( 0.029 - 0.179) 0.007 0.294 ( 0.078 - 0.511) 0.008 
Table 3. Post hoc analyses investigating SNP associations stratified by levels of 
childhood maltreatment with the risk of recurrent depressive episodes in our 
discovery Radiant, and replication Münster samples. Analyses were adjusted for 
gender. CM category = childhood maltreatment category; CI = confidence intervals. 
Bold value: p-value < 0.05 
 
We also investigated sub-types of childhood maltreatment as post-hoc 
exploratory analyses (sexual abuse, physical abuse, emotional abuse, 
physical neglect, and emotional neglect) in loci suggestive of significance. We 
report significant interactions between all the childhood maltreatment sub-
types and rs1818879 (IL-6) (Sexual Abuse: RD = 0.088, SE = 0.037, p = 
0.018; Physical Abuse: RD = 0.198, SE = 0.026, p < 0.001; Emotional Abuse: 
RD = 0.074, SE = 0.022, p = 0.001; Emotional Neglect: RD = 0.086, SE = 
0.024, p < 0.001; Physical Neglect: RD = 0.054, SE = 0.023, p = 0.017), and 
risk for recurrent depression in the discovery Radiant cohort, however this is 
not seen in the replication Münster cohort (NS). In contrast, rs3093077 (CRP) 
presented no significant interactions with maltreatment sub-types in the 
discovery study, although there was some evidence for significant interactions 
with physical abuse (RD = 0.146, SE = 0.047, p = 0.002), and emotional 
abuse (RD = 0.133, SE = 0.042, p = 0.002) in the replication study. For 
complete maltreatment sub-type analyses see Supplementary Table 9. 
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4. Discussion 
 
We found evidence for interaction between childhood adversity and one SNP 
in IL-6 (rs1818879) in the RADIANT sample; the Münster replication sample 
also presented evidence prior to correction, which reduced to very close to 
significance following correction for multiple testing. It is notable that for 
replication, we maintained two-tail significance tests; had a one-tail test been 
applied this would have reached significance even following correction. Due to 
the controversies that have arisen in GE depression research to date, we 
erred on the side of caution using the two-tail statistic which is what was 
applied in the discovery sample. However meta-analysis of the two samples 
supported the interaction. It is possible that our replication sample, although 
closely similar to our discovery sample, possessed reduced statistical power 
relative to the discovery sample because: i) the discovery Radiant sample 
control participants were both themselves and their first-degree relatives free 
of psychiatric history, in contrast to the replication sample which did not 
consider first-degree relative psychiatric history; and ii) the Radiant sample 
was restricted to case individuals that had experienced moderate to severe 
episodes of recurrent depression, a criterion not applied to the Münster 
sample. Thus the discovery sample may have been better powered because 
the affected individuals represented a more extreme phenotype, and the 
sample of individuals with recurrent MDD was greater in the discovery relative 
to the replication sample. When analyses for this SNP were expanded to the 
entire Münster sample, including individuals that had not suffered recurrent 
episodes of depression, effects and significance dropped markedly. It is 
plausible that carrying rs1818879 (IL-6) minor alleles in conjunction with 
exposure to significant childhood maltreatment may increase risk to a more 
severe and recurrent form of MDD, and robust replication will only be seen in 
cohorts reflective of this phenotype. Our post-hoc analyses investigating 
different sub-types of childhood maltreatment suggest that, if a true effect, the 
genetic risk of the minor allele may be specific to individuals that have 
experienced abuse-related maltreatment rather than neglect-related 
maltreatment. However this certainly needs to be further explored in larger 
cohorts. 
 
Our findings support previous research indicating that IL-6 is implicated in 
gene-environment interactions in depression, where rs1800795 interacted 
with interpersonal stress exposure in Australian youth, predicting depressive 
symptoms (Tartter et al., 2015). However, rs1800795 was not the same 
variant that we identified in this cohort. The IL-6 variant that we found 
supporting evidence was rs1818879. This is an interesting SNP located 
downstream of the IL-6 gene; it has been associated with severe influenza A 
virus infection (minor allele) (García-Ramírez et al., 2015) and body mass 
index (major allele within a large haplotype) (Qi et al., 2007). IL-6 gene-
expression, and protein-expression, have been associated with depression 
and with childhood maltreatment. However, notably although rs1818879 is an 
eQTL, it is associated with AC073072.5 expression, an antisense gene to IL-6 
coding for long non-coding RNA (lncRNA). Expression of AC073072.5 has not 
been studied although the functional impact of lncRNAs (Pelechano and 
Steinmetz, 2013), and significance in psychiatric illness such as depression 
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(Huang et al., 2016) and the stress response (Amaral et al., 2013) are 
becoming clear.  
 
Although there is evidence for a dysregulation in IL-6 proteins in depressed 
individuals, the literature isn’t completely consistent. This could, in part, be 
due to the role of childhood maltreatment as IL-6 levels have also been 
associated with childhood maltreatment exposure. Thus if studies investigated 
depression in the context of childhood maltreatment exposure, their findings 
may become more consistent. It could also be due to the impact of this 
antisense gene, and related lncRNA transcripts, which may directly interact 
with IL-6 and/or other inflammation related mRNAs. 
 
The findings for the CRP locus (rs3093077) present a similar pattern with the 
meta-analysis of the two samples showing significant evidence for the GE 
interaction. However, the data present a less compelling case than that found 
for the IL-6 locus. This could be a consequence of low minor allele frequency 
and thus warrants some discussion. In the replication sample alone 
rs3093077 showed no GE interaction effect until the sample was expanded to 
include more broad MDD cases, including individuals that had only 
experienced single episodes of MDD. This is opposite to the pattern observed 
with the IL-6 SNP. This could be due to a low minor allele frequency and thus 
reduced power resulting in non-detection of effect with the smaller more 
severe phenotypic sample, or it could simply be reflective of being a chance-
finding. Of note, the minor alleles of two SNPs in complete LD with rs3093077 
(rs11265260 and rs3093059) are significantly associated with CRP protein 
abundance in genome-wide association studies (Okada et al., 2011; Reiner et 
al., 2008); notably one of these studies identified an IL-6 locus (rs2097677) to 
also be associated with serum CRP protein abundance. In contrast to IL-6, 
researchers have investigated CRP protein levels in depressed cohorts in the 
context of childhood maltreatment and have presented evidence in adolescent 
and adult cohorts that CRP is elevated in those that are depressed or have a 
history of depression, and that this elevation is even greater in those that have 
experienced significant childhood maltreatment (Danese et al., 2008).  
 
Our findings indicate genetic support for the implication of immune pathways 
in depression, in context of childhood maltreatment. Mechanisms by which 
gene-environment interactions have their effect have been discussed (e.g. 
Cohen-Woods et al., 2013), including epigenetic mechanisms. Childhood 
maltreatment has been demonstrated to alter DNA methylation (Bick et al., 
2012); it is plausible that childhood trauma could alter the epigenetic profile of 
individuals, potentially activating (or switching off) a risk genotype. For 
example, childhood maltreatment may alter DNA methylation in the IL-6 
promoter or enhancers, potentially altering gene-expression and protein-
expression. This may influence risk for inflammation, and in turn, depression.  
 
We must note however that effect sizes are small, as expected in genetic 
studies, meaning clinical relevance will only be achieved when multiple GE 
SNPs have been identified, as with a polygenic risk score, to identify those at 
risk in particular adverse environments. Focusing on specific systems (e.g. 
functional SNPs and eQTLs in the immune system) could aid this. 
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Significantly, the literature does indicate there is a sub-group of MDD 
individuals that exhibit elevated levels of peripheral inflammation (Raison and 
Miller, 2011); thus some individuals with MDD show elevated inflammation 
whilst others do not. It is possible, and plausible, that the interaction we report 
here is related to an inflammation sub-group; individuals with a history of 
childhood maltreatment and IL-6 risk variant, may also exhibit higher levels of 
inflammation. Further, inflammation-based restriction to MDD groups in 
studies (i.e. those with elevated inflammation in the periphery separated from 
those with no elevated inflammation in the periphery) may enhance effect 
sizes when studying inflammation pathway genes in both genetic and GE 
studies. This needs to be explored further, although it does require collection 
of plasma or serum, in addition to blood for genetic testing. Exploring if 
childhood maltreatment may account for previously reported sub-types of 
inflammation-based depressions would be valuable, and could also be 
another pathway by which the reported GE interactions occur in these genes. 
 
It is interesting that we failed to replicate in the other genes where SNPs were 
identified in the discovery sample (e.g. TNF, and its receptors). This could be 
due to issues with power, however the effect sizes and directions indicates 
this is unlikely. It is possible that different aspects of the complex inflammation 
pathway may have differing roles. Interestingly the most convincing GE 
interaction we report with IL6 is with an eQTL for the antisense gene to IL-6 
that codes for a lncRNA; perhaps genetic variation within the immune system 
that alters non-coding RNA is more salient than other variation.  
 
This study addresses many concerns previously described in the literature 
with gene-environment interaction studies, addressing clear a priori 
hypotheses, with full reporting of all tests applied (and resulting statistics), and 
correcting for multiple testing. Limitations however do exist, including 
relatively limited sample sizes, a focus on additive genetic models (not 
evaluating multiplicative models due to the burden of multiple testing), the 
retrospective assessment of childhood maltreatment, and restriction of 
analyses to clinical depression. Further, our conclusions are restricted only to 
the genes that we included in our study; broader study of the immune system 
in context of childhood maltreatment and risk of MDD would be warranted. 
However, if increasing the number of genes studied we would suggest 
additional cohorts to improve power, using a meta-analytical framework. 
Finally, including additional potential confounders in future analyses would be 
valuable including smoking and body mass index; we did not have this data 
across all samples in this study. 
 
5. Conclusion 
Here we present suggestive evidence for novel interaction loci in IL-6 
(rs1818879) and potentially CRP (rs3093077) in the context of childhood 
maltreatment, increasing risk of recurrent depression (IL-6) and non-recurrent 
depression (CRP). Although we have described and discussed the results for 
both these SNPs, we must highlight that independent replication analyses fell 
short of significance, although relatively marginal in terms of rs1818879. To 
address restricted power we also ran meta-analyses of these loci, which 
present significant support for these interactions. However further 
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independent replication is necessary. It is important that these loci are 
pursued in larger samples, potentially with an international meta-analytic 
collaborative effort, and for case-control studies in the context of moderate to 
severe recurrent depression as well as more general diagnoses. Further 
investigation into multiplicative interaction models, and dominant/recessive 
genetic models in inflammation loci is warranted. 
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Highlights 
 
• Gene-environment study focusing on comprehensive analysis of immune 
candidate genes  
• Interaction with childhood maltreatment in predicting recurrent depression 
• Loci identified in the discovery sample taken forward to an independent 
replication sample 
• Two loci present some evidence for replication in IL-6 and CRP  
• These loci should be targeted for replication in further studies internationally 
in the future 
 
